OasisLMS

Take an exclusive look at emerging cardiovascular innovation from the 2025 HeartX cohort, MedAxiom and HealthTech Arkansas’s accelerator focused on supporting early-stage companies advancing cardiovascular care.

This session features:

StemCardio Medical is pioneering a non-invasive therapy for atrial fibrillation through a wearable device that combines proprietary neuromodulation with AI-powered cardiac rhythm monitoring to support personalized management at home.

CathVision will highlight its ECGenius system, which delivers high-fidelity, noise-cancelling cardiac signals to support ablation decisions. Its technology also provides real-time tissue feedback during pulsed field ablation and identifies focal AFib drivers to help guide more precise interventions.

FibriCheck will showcase its FDA-cleared platform for remote AFib detection and monitoring, using smartphone-based assessments and AI-powered reporting to support clinical workflows, informed decision-making, and expanded access to at-home rhythm monitoring.

Margaux Casteur, Director of US Growth, FibriCheck
Michael Iversen, Chief Commercial Officer, LUMA Vision
Amir Soltanianzadeh, CEO, StimCardio